Early Alzheimer’s patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb)…
Data showed LEQEMBI slowed clinical decline by 1.75 points on CDR-SB at four years compared to the natural history of Alzheimer’s…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Eisai Co
FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment
LEQEMBI’s subcutaneous formulation could simplify maintenance therapy for Alzheimer’s patients, offering a 15-second at-home…
Eisai to grant 625 mn yen to GHIT Fund for developing medicines for neglected tropical diseases,…
Eisai has participated in 23 joint research projects to develop new medicines and vaccines for mycetoma, malaria and filariasis,…
Eisai submits MAA for lecanemab in Great Britain to treat early Alzheimer’s disease
Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway
Eisai enters into agreement with Blissbio for antibody-drug conjugate BB-1701
Based on the status of Phase I/II clinical trials of BB-1701 currently being conducted by BlissBio, both companies have decided to…
Biogen scraps two late-stage trials for Alzheimer’s treatment
The decision was based on the results of a review conducted by a data safety monitoring board, which recommended discontinuing the…
DRL in agreement with Eisai Co, Japan
Acquires rights to Investigational Anticancer Agent E7777 for US, Europe and certain emerging markets from Eisai